Stock Trading

CEXI

CDEX Inc. Commences Debt Restructuring to Strengthen Company's Future Competitiveness

(Marketwire) -- 02/10/12 -- CDEX Inc. (OTCBB: CEXI) today announced that to achieve a debt structure that would allow the Company to continue to develop its leading edge products in the healthcare markets with the ValiMed G4 medication safety system and in the security market with its ID2 Meth Scanner and Pocket ID2 Meth Scanner it has retained the law firm of Eric Slocum Sparks, P.C. to assist in the financial restructuring through the voluntary filing of a Chapter 11 reorganization in the United States Bankruptcy Court for the District of Arizona. During the restructuring, the Company intends to continue operating as normal, without interruption.

The Company's Board of Directors determined that Chapter 11 reorganization provides the most effective and efficient means to restructure with minimal impact on the business, and is in the best interest of the Company, its stakeholders and customers. "Although the Company has worked closely with its noteholders and other creditors and constituents over the past year, which led to the reduction of certain obligations, the Company needs to complete its comprehensive restructuring due to its current inability to negotiate restructuring terms with all noteholders," said Jeffrey Brumfield, Chairman and Chief Executive Officer of CDEX.

CDEX intends to file motions with the Court to ensure the Company's ability to continue its normal operations, including the ability to continue the development, sale and service of all of its products. The Company anticipates receiving approval from the Court within the next several days. "All forms of debt incurred prior to the commencement of the Company's Chapter 11 case that have not been paid is intended to be resolved through the Company's Plan of Reorganization," said Brumfield.

"Throughout this restructuring process, we are committed to working as quickly and efficiently as possible to appropriately restructure CDEX so that it can emerge from Chapter 11 as a strong company, well-positioned to compete effectively in the marketplace," continued Brumfield.

CDEX Inc. (CDEX) develops manufactures and distributes products for the healthcare and security markets. The company focuses its resources on marketing and improving real-time chemical detection products using patented technologies. CDEX creates reference signatures of substances of interest, such as selected narcotics, explosive compounds and medicines. CDEX primary area of focus is on products in the healthcare market and security markets. Its Healthcare Market line includes ValiMed™ Medication Validation System (MVS) product line, which includes validation of substances, training and quality assurance. Its Security Market includes the ID2 Product Line, which comprise real time detection of specified illegal drugs in a portable handheld device.

---------------------------------------------------

CDXC

ChromaDex® Announces the Closing of Common Stock Sale with Gross Proceeds of $11.175 Million

IRVINE, Calif., Feb. 10, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today that it closed the previously announced registered direct offering of common shares at a price per share of $0.75. The company sold 9,966,666 shares of common stock for gross proceeds of approximately $7.475 million. The shares were offered by ChromaDex Corporation pursuant to a shelf registration statement on Form S-3 previously declared effective by the Securities and Exchange Commission.


The company also closed the previously announced sale to investors including several members of ChromaDex's management of 4,933,329 restricted shares of common stock at a price per share of $0.75 per share for gross proceeds of approximately $3.7 million.

ChromaDex Corporation plans to use the net proceeds from the offerings primarily to fund its recently launched BluScience™ retail consumer line, and for general working capital purposes.

Aegis Capital Corp. acted as the sole placement agent for the offerings.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the prospectus supplement together with the accompanying prospectus can be obtained at the Securities and Exchange Commission's website at http://www.sec.gov or from Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 11th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements, now available at Drugstore.com. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.


Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

ChromaDex/BluScience Contact:
Jeffrey Himmel, CEO
949-419-0288
jsh@chromadex.com

------------------------------------------

LUVU
QualityStocks.net - stock newsletters for smallcap companiesHomeAbout UsClientsConferencesMediaPartnersQuotes & NewsServicesRanked FirmsContact UsMarket Quotes & News
February 10, 2012 - 5:53 PM EST


Liberator, Inc. Announces the Retirement of 25 Million Shares

, GA -- (Marketwire) -- 02/10/12 -- Liberator, Inc. (OTCBB: LUVU) (OTCQB: LUVU), a dynamic high-growth and vertically integrated company capitalizing on the emerging sexual wellness revolution through the worldwide marketing of the Liberator® brand, today announced it has retired approximately 25 million shares of common stock, equating to a 27% reduction in the number of shares outstanding.

The retirement of these shares occurred in connection with the company's November 2011 sale of its former subsidiary, Web Merchants Inc. ("WMI"). The company shares, which were owned by the former president and majority shareholder of WMI, Fred Petrenko, were released from escrow and retired following satisfaction of certain conditions described in the agreements for the sale of WMI.

Immediately following retirement of the 25,394,400 shares, there were 67,002,647 shares of common stock issued and outstanding. Management believes the retirement of these shares demonstrates a commitment to common shareholders as the company strives to enhance shareholder value.

"We view this as a very positive step forward in improving the overall capital structure of our company," said Louis Friedman, President and CEO of Liberator, Inc. "By reducing our issued and outstanding common shares, we will add value to both our new and existing shareholders, while Liberator continues to improve revenues and implement our strategic growth initiatives in 2012 and beyond."

About Liberator, Inc.

Liberator, Inc. is a dynamic high-growth and vertically integrated public company capitalizing on the emerging sexual wellness revolution through the worldwide marketing of the Liberator® line of products, the luxury and lovestyle brand that celebrates intimacy by inspiring romantic imagination. Established with the conviction that sensual pleasure and fulfillment are essential to a well-lived life, Liberator Bedroom Adventure Gear® empowers exploration, fantasy and the communication of desire, for persons of all shapes, sizes and abilities. Products include Liberator shapes and positioning systems, pleasure objects, and sensual accessories. Liberator, Inc. is currently housed in a 140,000 square foot vertically integrated manufacturing facility in a suburb of Atlanta, Georgia. Liberator, Inc. has over 100 employees, with products being sold directly to consumers and through hundreds of domestic resellers, on-line affiliates and six international licensees. The company is known for cutting-edge advertising and product branding. Since inception in 2002, Liberator has sold over $60 million of branded Liberator products.

Liberator operates an online retail e-commerce website at: www.Liberator.com and can be followed on Twitter at: www.twitter.com/Liberator.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements that reflect the company's current expectations and projections about future results, performance, prospects and opportunities. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that may cause actual results, performance, prospects or opportunities to be materially different from those expressed in, or implied by, such forward looking statements. You should not place undue reliance on any forward-looking statements. Except as required by federal securities law, the company assumes no obligation to update publicly or to revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available, new events occur or circumstances change in the future.

Company Contact:

Liberator, Inc.
Ronald Scott
Chief Financial Officer
770-246-6426
Email Contact

Financial Communications Contact:

Trilogy Capital Partners
Darren Minton
President
Toll-free: (800) 592-6067
Email: Email Contact

__________________
FYI when I post I do not link charts as you and I have diff settings and we both know charts can turn on a moments notice.
Please do your own DD as I can only be held responsible if/when you make $$$$$$!